Amneal Pharmaceuticals (AMRX) News Today $8.53 -0.36 (-4.05%) Closing price 04:00 PM EasternExtended Trading$8.54 +0.01 (+0.12%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Buy" from AnalystsAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received an average rating of "Buy" from the five ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price amMarch 25 at 4:24 AM | marketbeat.comMagnetar Financial LLC Buys Shares of 47,804 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Magnetar Financial LLC bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 47,804 shares of the company's stock, valued at approximateMarch 24 at 4:42 AM | marketbeat.comIntech Investment Management LLC Has $642,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Intech Investment Management LLC raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 120.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 81,055 shares of the company's stock after purchasing an additional 44,208 shares duMarch 24 at 4:14 AM | marketbeat.com31,764 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by AmundiAmundi acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,764 shares of the company's stock, valued at approximately $256,000. Other instituMarch 22 at 3:28 AM | marketbeat.comCharles Schwab Investment Management Inc. Has $12.20 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Charles Schwab Investment Management Inc. lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,539,934 shares of the company's stock after buying an addMarch 22 at 3:09 AM | marketbeat.comAmneal Pharmaceuticals (AMRX) Gets a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comAmneal Pharmaceuticals: Shares Still Feel Significantly UndervaluedMarch 19, 2025 | seekingalpha.comVictory Capital Management Inc. Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Victory Capital Management Inc. increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 112.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 211,130 shMarch 19, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Major Shareholder Tushar Bhikhubhai Patel Sells 5,000,000 SharesAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.March 18, 2025 | marketbeat.comTushar Bhikhubhai Patel Sells 5,000,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockMarch 18, 2025 | insidertrades.comAmneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s TreatmentMarch 17, 2025 | markets.businessinsider.comAmneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growthMarch 14, 2025 | investing.comAmneal to Participate at Upcoming Investor ConferenceMarch 10, 2025 | businesswire.comAlphaQuest LLC Boosts Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)AlphaQuest LLC grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,462.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 157,623 shares of the company's stock after acquiring an additionalMarch 10, 2025 | marketbeat.comInsider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 80,000 Shares of StockAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the sale, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.March 6, 2025 | marketbeat.comAmneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDAMarch 4, 2025 | markets.businessinsider.comHandelsbanken Fonder AB Acquires Shares of 39,000 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Handelsbanken Fonder AB acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 39,000 shares of the company's stock, valMarch 4, 2025 | marketbeat.comAmneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDAMarch 3, 2025 | businesswire.comAmneal Pharmaceuticals price target raised to $11 from $10 at BarclaysMarch 3, 2025 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $11.00Barclays boosted their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday.March 3, 2025 | marketbeat.comNew York State Common Retirement Fund Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)New York State Common Retirement Fund boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 24.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 220,627 shares of the company's stock after purchasingMarch 3, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Misses Expectations By $0.03 EPSAmneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) issued its quarterly earnings data on Friday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter last year, the business earned $0.14 EPS.March 2, 2025 | marketbeat.comAmneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses ExpectationsMarch 1, 2025 | uk.finance.yahoo.comIs Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts?March 1, 2025 | insidermonkey.comIs Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts?March 1, 2025 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | insidermonkey.comAmneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance. The company provided EPS guidance of 0.650-0.700 for the period, compared to the consensus estimate of 0.710. The company also issued revenue guidance of $3.0 billionillion-$3.1 billionillion, compared to the consensus estimate of $2.9 billionillion.March 1, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comAmneal Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 28, 2025 | seekingalpha.comAmneal Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 15cFebruary 28, 2025 | markets.businessinsider.comAmneal Pharmaceuticals sees FY25 adjusted EPS 65c-75c, consensus 71cFebruary 28, 2025 | markets.businessinsider.comAmneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year SalesFebruary 28, 2025 | msn.comAmneal Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 | businesswire.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Recommendation of "Buy" from BrokeragesShares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have earned a consensus recommendation of "Buy" from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average tweFebruary 28, 2025 | marketbeat.comAmneal Pharmaceuticals Q4 2024 Earnings PreviewFebruary 27, 2025 | msn.comIs Amneal Pharmaceuticals, Inc. (AMRX) the Best Low Price Pharma Stock to Invest In Right Now?February 27, 2025 | insidermonkey.comAnalysts Are Bullish on Top Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Revolution Medicines (RVMD)February 27, 2025 | markets.businessinsider.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Phocas Financial Corp.Phocas Financial Corp. reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 80.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,889 shares of the company'sFebruary 26, 2025 | marketbeat.comAmneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorganFebruary 25, 2025 | markets.businessinsider.comAmneal stock climbs 10% amid J.P. Morgan upgradeFebruary 25, 2025 | msn.comAmneal Pharmaceuticals (NASDAQ:AMRX) Shares Gap Up - What's Next?Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Gap Up - Still a Buy?February 24, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by JPMorgan Chase & Co.JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $9.00 to $12.00 in a research note on Monday.February 24, 2025 | marketbeat.comHussman Strategic Advisors Inc. Buys 42,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Hussman Strategic Advisors Inc. increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 252,000 shares of the company's stock aFebruary 21, 2025 | marketbeat.comAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideFebruary 19, 2025 | finance.yahoo.comAmneal launches Mesalamine; receives U.S. FDA Lenalidomide approvalFebruary 19, 2025 | markets.businessinsider.comGeneric Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The RestFebruary 19, 2025 | msn.comConvergence Investment Partners LLC Increases Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Convergence Investment Partners LLC raised its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,February 19, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in JanuaryAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,420,000 shares, a decrease of 18.0% from the January 15th total of 2,950,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is currently 2.0 days. Approximately 1.9% of the company's shares are short sold.February 15, 2025 | marketbeat.comEntropy Technologies LP Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Entropy Technologies LP purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 32,757 shares of the company's stock, valued at approximatelFebruary 14, 2025 | marketbeat.comAlthough Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stakeFebruary 13, 2025 | finance.yahoo.com Remove Ads Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼1.190.62▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼94▲AMRX Articles Average Week Remove Ads Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News Today SRPT News Today PCVX News Today QGEN News Today ROIV News Today RVMD News Today LNTH News Today LEGN News Today TGTX News Today BBIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRX Stock Free AMRX Stock Alerts